Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
about
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanismComparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptaseMultidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapySelective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile anCombination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosineThe nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 yearsAntiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strainsDrug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA.Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosineClinically relevant genotype interpretation of resistance to didanosineA novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidineThe impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificityConvergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assayGenotypic testing for human immunodeficiency virus type 1 drug resistance.Analysis of human immunodeficiency virus type 1 reverse transcriptase subunit structure/function in the context of infectious virions and human target cells.Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.Antiretroviral therapy for human immunodeficiency virus infection in 1997.Resistance and cross-resistance to abacavir.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase.Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidineMutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaquesJE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosidesAttenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working GroupAntiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.
P2860
Q21135752-1C09C187-4230-4907-BC61-4676F3385632Q24550959-B7BE479C-A416-44B2-8E50-2311C5372BF3Q24684152-1A11747E-AFBF-4E04-B698-2DE0EC1D0224Q28378760-0F53751B-D8D9-4BBA-8772-9C7B78F1191FQ28378896-95A6A133-03CC-41E6-9F4D-74307824F7B4Q28378965-17B6135E-EAF1-4C09-9A41-11354AFDA75FQ28379139-61FB3BA9-7DDF-4CA2-9B4E-24A517D7446AQ28379519-43741930-32AD-4656-BA44-FD120F6C8E99Q28379552-FF109517-9263-41B2-9BB0-A9141515706EQ31430709-19E8D724-E92E-47A4-95BC-6A9C534B0F7EQ33513336-C9FDCED0-6AE7-4A31-9553-581636133448Q33769970-ABF7A09C-9ED6-4C14-ADB9-A670BD1EF717Q33770146-A138A81D-3487-48EA-8A35-8FEDD280B4C9Q33782477-50408B1E-2674-44D1-91CE-CC694EB18E1FQ33783072-D2A28D68-B4F8-4564-A106-5E924D6236C3Q33787173-32221AED-59AB-43FD-A711-FCDCD20246E4Q33811164-226AA682-C292-4990-8ABA-6DE11C162550Q33814927-178668F8-0B6F-4138-96BF-82FC3B65C24CQ33906239-1F0593CB-0D9F-453F-B8A0-125DECF082B1Q33935269-0451C910-515F-425E-9D76-15A659A7B5F0Q33962513-0771480A-53FD-40F2-B3C2-AE9ED9AE0F54Q34185841-D182B6E8-FB8F-41F5-BEF3-10FD7DCE9037Q34459409-12E40C1D-1E5D-482D-BF68-2D0C72700D08Q34489239-B01BAA88-DE22-4D8C-A8F3-3A55C0C31ACFQ34594711-E8E42EFB-FD24-45D6-BF98-F4F5D02506F5Q34789834-34823BDB-BF2F-4FF4-B866-80B719DA6222Q35104511-4E4D12A7-6807-4913-B1CA-5839038E6734Q35123759-E07A0DE1-D9F7-4A57-AE00-1A0D63AE5100Q35126454-5C444AA6-1C25-46B7-9FC1-B741E6149614Q35130447-A72B72AF-362A-4155-8892-9F5DC413CFDAQ35132138-8BB5E5DF-CA3E-49E5-9A84-BDD925701C79Q35560481-8B6906F9-4347-4453-868A-F08AA42666B7Q35633587-7172F3DF-7A6B-4C3D-9245-60CC4EE44BEEQ35742512-704AD950-B3EF-42F9-819D-466E0F58A2A3Q35839770-6C4FF454-D716-4F02-9B8B-F0F8BF56DF1AQ35870930-521E957D-32E2-406E-9CB0-3B7AC328EF4CQ35879410-81BC3037-4AF7-498B-A3EB-D7D3FBA4C649Q35899105-1DB1C9DE-F1D4-4879-9D6F-0E4AD87473C9Q36536351-82562BC3-90DD-4D98-9417-A0119F731E43Q36684283-F32E69E3-0542-44D7-8052-652FCDC5F93D
P2860
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Combination therapy with zidov ...... atterns of pol gene mutations.
@ast
Combination therapy with zidov ...... atterns of pol gene mutations.
@en
Combination therapy with zidov ...... atterns of pol gene mutations.
@nl
type
label
Combination therapy with zidov ...... atterns of pol gene mutations.
@ast
Combination therapy with zidov ...... atterns of pol gene mutations.
@en
Combination therapy with zidov ...... atterns of pol gene mutations.
@nl
prefLabel
Combination therapy with zidov ...... atterns of pol gene mutations.
@ast
Combination therapy with zidov ...... atterns of pol gene mutations.
@en
Combination therapy with zidov ...... atterns of pol gene mutations.
@nl
P2093
P356
P1476
Combination therapy with zidov ...... patterns of pol gene mutations
@en
P2093
A K Iversen
D A Katzenstein
M A Winters
R W Shafer
P304
P356
10.1093/INFDIS/169.4.722
P407
P577
1994-04-01T00:00:00Z